{"id":"W3004714210","doi":"10.1111/bjh.16462","title":"Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","year":2020,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; St. Paul's Hospital; University of British Columbia","funders":"AOP Orphan; Incyte; Baxalta; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; Alexion Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Teva Pharmaceutical Industries; Gilead Sciences; Sanofi; Bristol-Myers Squibb","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Discontinuation; Internal medicine; Cohort; Adverse effect; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000373375,0.0001268501,0.001097293,0.0001655188,0.00005696228,0.00001829691,0.0001009659,0.0000411332,0.00005820375],"category_scores_gemma":[0.0001938046,0.00008320615,0.00007152757,0.0004642325,0.0001133984,0.00009360556,0.00005668812,0.0001892056,2.822941e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003026729,"about_ca_system_score_gemma":0.0001457031,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004162349,"about_ca_topic_score_gemma":0.00005342205,"domain_scores_codex":[0.9983553,0.0002024115,0.0007027248,0.0001757732,0.0004184175,0.0001454199],"domain_scores_gemma":[0.9984869,0.0003509145,0.0006386199,0.0001019852,0.0003305344,0.00009105429],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005937208,0.00249704,0.9706956,0.0001517265,0.002031699,0.001846094,0.001390458,0.0001086582,0.00002844023,0.000009967633,0.00003819806,0.01526488],"study_design_scores_gemma":[0.02279306,0.006534855,0.9657765,0.0009745698,0.001692115,0.001154022,0.0004176739,0.0001658,0.0003936437,0.000003696993,0.000006305396,0.0000877791],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983947,0.0006837535,0.00004218409,0.000166608,0.00001653432,0.0005735725,0.00003557531,0.00000310182,0.00008402004],"genre_scores_gemma":[0.9992554,0.0002004667,0.0003403851,0.0001457386,0.00001603338,0.000009110701,0.00001905965,0.0000120694,0.000001716662],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01685585,"threshold_uncertainty_score":0.3393048,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04091387740162374,"score_gpt":0.3584157042767382,"score_spread":0.3175018268751145,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}